ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

HHS Back down, Says Now It Will Support Survey Of Research Facilities

October 28, 1983

Varmus: NCI Faces “Budgetary Disaster;” Flat Funds, Cuts Loom For Most Programs

January 14, 2011

ASCO Annual Meeting: PARP Inhibitors Show Promise Against Breast Cancer In Small Phase II Studies

June 5, 2009

In Aftermath of NEJM Article, Critic Bailar Declares The Defeat Of Cancer Treatment

June 6, 1997

NCAB, Panel May Look A Discrepancies, In Study Section Evaluation Of Grant Applications

September 4, 1981

DCT Board Approves $8 Million In Contract Projects For Recompetition

October 31, 1980